Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2009-06-26
2011-12-27
Solola, Taofiq A (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
Reexamination Certificate
active
08084498
ABSTRACT:
The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
REFERENCES:
patent: 3441605 (1969-04-01), Blake
patent: 3773946 (1973-11-01), Creger
patent: 3930024 (1975-12-01), Creger
patent: 4287200 (1981-09-01), Kawamatsu
patent: 4584321 (1986-04-01), Manqhisi et al.
patent: 4613593 (1986-09-01), Yamatsu et al.
patent: 4634719 (1987-01-01), Takaishi et al.
patent: 4689344 (1987-08-01), Bar-Tana
patent: 4711896 (1987-12-01), Bar-Tana et al.
patent: 5502198 (1996-03-01), Picard et al.
patent: 5504073 (1996-04-01), Homan
patent: 5578639 (1996-11-01), Homan
patent: 5633287 (1997-05-01), Lee et al.
patent: 5648387 (1997-07-01), Bisgaier et al.
patent: 5750569 (1998-05-01), Bisgaier et al.
patent: 5756344 (1998-05-01), Onda et al.
patent: 5756544 (1998-05-01), Bisgaier et al.
patent: 5783600 (1998-07-01), Bisgaier et al.
patent: 5968963 (1999-10-01), Homan
patent: 5981595 (1999-11-01), Picard et al.
patent: 6017905 (2000-01-01), Roark et al.
patent: 6093719 (2000-07-01), Bocan
patent: 6093744 (2000-07-01), Lee et al.
patent: 6124309 (2000-09-01), Bocan
patent: 6143755 (2000-11-01), Bocan
patent: 6699910 (2004-03-01), Dasseux et al.
patent: 2003/0078239 (2003-04-01), Dasseux et al.
patent: 2004/0198814 (2004-10-01), Dasseux
patent: 9630328 (1996-10-01), None
patent: 9830530 (1998-07-01), None
patent: 9900116 (1999-01-01), None
patent: 0064911 (2000-11-01), None
patent: 0146110 (2001-06-01), None
patent: 0230860 (2002-04-01), None
Acton et al., 1996, “Identification of Scavenger Receptor SR-BI as a high density lipoprotein receptor”, Science 271 :518-520.
Badimon et al., 1992, “Role of high density lipoproteins in the regression of atherosclerosis”, Circulation 86(Suppl. 111):86-94.
Barrans et al., 1996 “Pre-beta HDL: structure and metabolism”, Biochem. Biophys Acta 1300:73-85.
Bisgaier et al., 1998, “A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor”, J. Lipid Res. 39:17-30; (1998).
Brown and Goldstein, 1990, “Drugs used in the treatment of hyperlipoproteinemias”, In: The Pharmacological Basis of Therapeutics, 8th Ed., Goodman & Gilman, eds., Pergamon Press, Ch. 36 pp. 874-896.
Bruce et al., 1998, “Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport” Annu. Rev. Nutr. 18:297-330.
Dansky and Fisher, 1999, “High-density lipoprotein and plaque regression: the good cholesterol gets even better” Circulation 100:1762-1763.
Decossin et al., 1997, Subclasses of LpA-I in coronary artery disease: distribution and cholesterol efflux ability, Eur. J. Clin. Invest. 27:299-307.
Fielding and Fielding, 1995, “Molecular physiology of reverse cholesterol transport”, J. Lipid Res. 36:211-228.
Gearing et al., 1993, “Interaction of the peroxisome-prolifertor-activated receptor and retinoid X receptor”, Proc. Natl. Acad. Sci. USA 90:1440-1444.
Harris and Kletzien, 1994, “Localization of pioglitazone response element in the adipocyte fatty acid-binding protein gene”, Mol. Pharmacol. 45:439-445.
Heyman et al., 1992, “Affinity purification of the hepatic high-density lipoprotein receptor identifies two acidic glycoprotins and enables further characterization of their binding properties”, Biochem. J. 284:161-167.
Hidaka and Fedge, 1992, “Affinity purification of the hepatic high-density lipoprotein receptor identifies two acidic glycoproteins and enables further characterization of their binding properties”, Biochem. J. 284:161-167.
Hirano et al., 1997, “Genetic cholesterol ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity”, Aarterioscler, Thromb. Vasc. Biol. 17:1053-1059.
Issemann and Green, 1990, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators”, Nature 347:645-650.
Keller and Wahli, 1993, “Peroxisome proliferator-activated receptors—a link between endocrinoloov and nutrition” TEM 4:291-296.
Keller et al., 1993, “Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers”, Proc. Natl. Acad. Sci. A 90:2160-2164.
Kliewer et al., 1992, “Convergence of 9-cis retinoic acid and peroxisome proliferator signaling oathwavs through heterodimer formation of their receptors”, Nature 358:771-774.
Kurata et al., 1998, “A candidate high density lipoprotein (HDL) receptor, HB2, with possible multiple functions shows sequence homology with adhesion molecules”, J. Atheroscler. and Thromb.4:112-117.
Lagrost et al., 1996, “Opposite effects of cholesterol ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. Physiological relevance in alcoholic patients”, J. Biol. Chem. 271:19058-19065.
Landschulz et al., 1996, “Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidoqenic tissues of the rat”, J. Clin. Invest. 98:984-995.
Lazarow and Fujiki, 1985, “Biooenesis of peroxisornes”, Annu. Rev. Cell Biol. 1:489-530.
Levin et al., 1992, “9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRo”, Nature 355:359-361.
Nemali et al., 1988, “Comparison of constitutive and inducible levels of expression of peroxisomal p-oxidation and catalase genes in liver and extrahepatic tissues of rat”, Cancer Res. 48:5316-5324.
Parra et al., 1992, “A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study”, Arterioscler. Thromb. 707.
Reaven, 1993, “Role of insulin resistance in human disease (syndrome X): an expanded definition”, Annu. Rev. Med. 44:121-131.
Reddy and Lalwai, 1983, “Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans”, Crit. Rev. Toxicol. 12:1-58.
Rigotti et al., 1996, “Regulation by adrenocorticotropic hormone of the in vivo expression of scavenger receptor class B type I (SR-BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland”, J. Biol. Chem. 271 :33545-33549.
Robins and Fasulo, 1997, “High density lipoproteins, but not other lipoprotens, provide a vehicle for sterol transport to bile”, J. Clin. Invest. 99:380-384.
Staels and Auwerx, 1998, “Regulation of apo A-I gene expression by fibrates”, Atherosclerosis 137 (Suppl.):S19-S23.
Tontonoz et al., 1994, “Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPARyand RXRα”, Nucl. Acids Res. 22:5628-5634.
Vamecq and Draye, 1989, “Pathophysiology of peroxisomal β-oxidation”, Essays Biochem. 24: 115-225.
Nan F. et al. “Dual Function Glutamate-Related Ligands: Discovery of a Novel, Potent Inhibitor of Glutamate Carboxypeptidase II Possessing m
Dasseux Jean-Louis Henri
Oniciu Daniela Carmen
Brinks Hofer Gilson & Lione
Esperion Therapeutics, Inc.
Solola Taofiq A
LandOfFree
Ketone compounds and compositions for cholesterol management... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ketone compounds and compositions for cholesterol management..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ketone compounds and compositions for cholesterol management... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4258168